LifeSci Acquisition II Corp.
LifeSci Acquisition II Corp. (LSAQ) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
lsaq · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Shell Companies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
LifeSci Acquisition II Corp.You LSAQ | $1.1B | N/A | — | — |
 Amplitude Healthcare Acquisition Corporation AMHC | $1.1B | N/A | — | $0.00 |
 Churchill Capital Corp VII CVII | $915M | 78.44x | +105.0% | $0.13 |
 FG New America Acquisition Corp. FGNA | $1.1B | 1.81x | -95.3% | $5.52 |
 Franklin Pennsylvania Municipal Income ETF FTPA | $298M | N/A | — | -$0.01 |
 FTAC Hera Acquisition Corp. HERA | $1.1B | 34.54x | -9.7% | $0.28 |
 Humacyte, Inc. HUMA | $240M | N/A | — | -$0.26 |
Industry Average 3 peers with valid PE | — | 38.26x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for LifeSci Acquisition II Corp. (LSAQ) measures how much investors pay for each dollar of the company's trailing earnings. LSAQ's current PE ratio of N/A is calculated by dividing its stock price of $9.01 by its TTM earnings per share of —.
Frequently asked questions
LSAQ pe ratio · 6 questionsLSAQ's current PE ratio is N/A as of 2026-06-09, based on a stock price of $9.01 and TTM EPS of —. Data sourced from Financial Modeling Prep via LSAQ's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · LifeSci Acquisition II Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09